Transcatheter Mitral Valve Replacement and Thrombosis: A Review

Frontiers in Cardiovascular Medicine

Paolo Denti¹  Guido Ascione² 

[1] Department of Cardiac Surgery, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy;null;

关键词: transcatheter mitral valve replacement;    thrombosis;    vitamin K antagonists;    non-vitamin K antagonist oral anticoagulants;    mitral valve regurgitation;   

DOI  :  10.3389/fcvm.2021.621258

来源: Frontiers

【 摘 要 】

Mitral regurgitation is the most prevalent form of moderate or severe valve disease in developed countries. Surgery represents the standard of care for symptomatic patients with severe mitral regurgitation, but up to 50% of patients are denied surgery because of high surgical risk. In this context, different transcatheter options have been developed to address this unmet need. Transcatheter mitral valve replacement (TMVR) is an emergent field representing an alternative option in high complex contexts when transcatheter mitral valve repair is not feasible or suboptimal due to anatomical issues. However, TMVR is burdened by some device-specific issues (device malposition, migration or embolization, left ventricular outflow tract obstruction, hemolysis, thrombosis, stroke). Here we discuss the thrombotic risk of TMVR and current evidence about anticoagulation therapy after TMVR.

【 授权许可】

CC BY